ScreenerHero

ANNXAnnexin Pharmaceuticals AB (publ)

STO · SE · Healthcare · Biotechnology · annexinpharma.se
13.20SEK+3.13%Mkt Cap: 9.05M $P/E: —

Annexin Pharmaceuticals AB (publ), a clinical stage biotechnology company, develops drug candidates for the treatment of various cardiovascular diseases. It develops ANXV, a human recombinant protein and Annexin A5, natu…

Industry Peers

Biotechnology
Screen all
VRTX
Vertex Pharmaceuticals Incorporated
$138.82BUSDP/E 31.9
REGN
Regeneron Pharmaceuticals, Inc.
$85.87BUSDP/E 20.5
ARGX
ARGENX SE
$61.34BUSDP/E 39.8
ARGX
argenx SE
$65.05BUSDP/E 39.6
MRNA
Moderna, Inc.
$57.94BUSD
UCB
UCB SA
$45.95BUSDP/E 19.6
RVMD
Revolution Medicines, Inc.
$44.89BUSD
ONC
BeOne Medicines AG
$42.36BUSDP/E 67.2
RPRX
Royalty Pharma Plc Class A
$35.43BUSDP/E 32.6
ALNY
Alnylam Pharmaceuticals, Inc.
$31.61BUSDP/E 41.2
BNTX
BioNTech SE
$29.28BUSD
INSM
Insmed Incorporated
$27.47BUSD
ROIV
Roivant Sciences Ltd. Common Shares
$26.22BUSD
INCY
Incyte Corporation
$25.91BUSDP/E 16.2
GMAB
Genmab A/S
$20.86BUSDP/E 26.3
GMAB
Genmab A/S
$19.26BUSDP/E 26.6
ASND
Ascendis Pharma A/S
$16.61BUSDP/E 19.6
JAZZ
Jazz Pharmaceuticals plc
$16.51BUSDP/E 17.4
BBIO
BridgeBio Pharma, Inc.
$15.93BUSD
EXEL
Exelixis, Inc.
$13.40BUSDP/E 17.0

Key Statistics

Company
Market Cap9.05M $
Enterprise Value7.01M $
Revenue (TTM)—
Gross Profit—
Net Income (TTM)-3.53M $
Revenue/Share—
Last Price13.20 SEK
Fiscal Year EndDec 2025
MR QuarterMar 2026
Employees4
CountrySE
SectorHealthcare
IndustryBiotechnology
ISIN—
Valuation
P/E (Trailing)—
P/E (Forward)—
PEG—
EV/EBITDA-1.88
EV/Revenue—
P/S—
P/B6.27
EPS (TTM)-5.51
EPS (Forward)—
52W Range
11.0511% of range30.00
52W High30.00 SEK
52W Low11.05 SEK
Profitability
Gross Margin0.00%
Oper. Margin0.00%
EBITDA Margin0.00%
Profit Margin0.00%
ROE-147.97%
ROA-122.34%
Growth
Revenue Growth—
Earnings Growth—
Cash Flow & Leverage
Operating CF-3.53M $
CapEx (TTM)12.34K $
FCF Margin—
FCF Yield-25.54%
Net Debt-1.63M $
Net Debt/EBITDA0.44
Balance Sheet
Debt/Equity0.00
Current Ratio3.31
Quick Ratio3.20
Book Value/Sh2.042 SEK
Cash/Share2.418 SEK
Dividends
Fwd Div Rate—
Trail. Div Rate0.0000 SEK
Div. Yield—
5Y Avg Yield—
Payout Ratio0.00%
Ex-Div Date—
Pay Date—
Splits
Last Split1:100
Split DateMay 28, 2025
Analyst Consensus
Rating—
Target (Mean)75.00 SEK
Upside (mean)+468.2%
Target Range75.00 SEK – 75.00 SEK
# Analysts1
Ownership
Shares Out.7.17M
Float3.56M
Insiders55.36%
Institutions4.71%
Technical
SMA 5012.54 (+5.2%)
SMA 20015.80 (-16.4%)
Beta0.30
S&P 52W Chg18.16%
Avg Vol (30d)5.63K
Avg Vol (10d)7.67K
Technical Indicators
RSI (14)55.6
MACD0.0984
MACD Signal0.0165
MACD Hist.+0.0819
BB Upper13.35 SEK
BB Middle12.64 SEK
BB Lower11.94 SEK
BB Width11.13%
ATR (14)0.5440 SEK
Vol Ratio (20d)0.19x